The manufacturing process should remain the focus for severe febrile reactions in children administered an Australian inactivated influenza vaccine during 2010

Abstract

Influenza vaccine safety is an ongoing issue. In 2010, inactivated trivalent influenza vaccines (TIVs), Fluvax® and Fluvax Junior® manufactured by CSL Biotherapies (‘CSL’), Parkville, Australia, were associated with a marked increase in febrile seizures (FS) in children <5 years old. Extensive investigations initially failed to identify a root cause. The company's researchers recently published two papers outlining their latest findings. Cytokine responses to TIV were measured in paediatric whole blood assays (WBA); NF‐κB activation was assessed using a HEK293 cell line reporter assay. CSL suggest that the combination of new influenza strains (H1N1 A/California/7/2009 and B/Brisbane/60/2008), increased complexes of viral RNA and lipid in the vaccine, and inherent sensitivities of some children <5 years old caused elevated inflammatory responses resulting in FS. Whilst the papers provide insight into pathogenesis, much remains unclear. The WBA were from only 10 ‘healthy’ children, potentially affecting generalisability of the results and reliability of these in vitro tests in assessing future influenza vaccine safety. Increased fever rates (without FS) found in CSL TIV studies between 2005 and 2010 suggest a long‐standing contribution to reactogenicity from the manufacturing process. More detailed comparisons with non‐CSL vaccines would have helped elucidate the relative contribution of patient/strain factors and the manufacturing process. The focus remains on manufacturing process differences as the key causative factor of elevated febrile responses. Studies underway, of modified vaccines in young children, will determine whether reactogenicity issues have been successfully addressed and whether CSL TIV can be relicensed in children <5 years of age.

Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia

“…Although most FS cases resolved without sequelae, permanent neurologic damage occurred in 2 children. 36,37 In the United States, primary care clinicians are reported as being unlikely to recommend MMRV, 38 and in Germany, there has been a decline in varicella vaccination uptake. 9…”

Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder

“…18 As well as the active immunogenic substance, vaccine excipients (eg, sodium taurodeoxycholate and thimerosal) and the manufacturing process have been potentially implicated in some vaccine reactions, such as febrile convulsions in children administered the inactivated influenza vaccination in 2010. 19 Neurological events attributed to vaccines have also previously led to their cessation from use. A 1976 H1N1 influenza vaccine was withdrawn from use due to a small increase of Guillain-Barré syndrome (GBS) cases (leading to around an additional one case of GBS for every 100 000 vaccines).…”

Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

“…Traditional vaccines, such as whole-cell pertussis vaccines [ 1 ] or whole-virus influenza vaccines [ 2 ], are highly immunogenic, albeit at the price of significant local and systemic reactogenicity. To reduce reactogenicity, modern approaches incorporate split, subunit or recombinant antigens from which reactogenic contaminants such as lipopolysaccharide, DNA and RNA are removed.…”